PPI-461 / BioCryst Pharmaceuticals - LARVOL DELTA

Dose-ranging trial of PPI-461, a potent new pan-genotypic HCV NS5A inhibitor, in patients with HCV genotype-1 infection (AASLD 2011) - Presentation time: Nov 06 5:30 PM - 5:45 PM; P1b, N=24; PPI-461 dosed at 50-200mg QD for 3 days in hepatitis C pts was well-tolerated; Dosing at 50mg QD showed substantial antiviral efficacy, but the 100 and 200mg doses, appeared more effective; With these higher doses pts consistently achieved 3-4 log10 HCV RNA reductions in the first 1-2 days of treatment

P1b data • Hepatitis C Virus